Diagnostic accuracy of non-invasive methods detecting clinically significant portal hypertension in liver cirrhosis: a systematic review and meta-analysis

Rana, Ramesh; Wang, Shenglan; Li, Jing; Basnet, Shiva; Zheng, Liang; Chen, Yang

doi:10.23736/s0026-4806.19.06143-3

Cited by 4 publications

(6 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an unmet need for simple, reliable, noninvasive methods to assess CSPH. 7 This is the first study to investigate the association between serum GP73 level and HVPG.…”

Section: Discussionmentioning

confidence: 99%

“…However, HVPG, the gold standard, is difficult to become widely popularized owing to its invasiveness, cost, and high requirements for technicians and equipment. There is an unmet need for simple, reliable, noninvasive methods to assess CSPH 7 . This is the first study to investigate the association between serum GP73 level and HVPG.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, existing blood-based tests and models have limited diagnostic value for CSPH. 7 Golgi protein 73 (GP73) is a transmembrane protein on the Golgi apparatus that is generally expressed by bile duct epithelial cells in the ductal region but low or even not expressed in hepatocytes. 8,9 The serum GP73 level is closely related to the degree of liver damage and is a validated noninvasive biomarker for the diagnosis of liver inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Liu,

Ma,

Chen

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatic venous pressure gradient (HVPG) is the gold standard for evaluating clinically significant portal hypertension (CSPH). However, reliable noninvasive methods are limited. Our study aims to investigate the diagnostic value of serum Golgi protein 73 (GP73) for CSPH in patients with compensated cirrhosis. The study enrolled 262 consecutive patients with compensated cirrhosis from three centers in China from February 2021 to September 2023, who underwent both serum GP73 tests and HVPG measurements. CSPH was defined as HVPG ≥ 10 mmHg. Diagnostic accuracy was evaluated using the areas under the receiver operating characteristic curve (AUC). The prevalence of CSPH was 56.9% (n = 149). There were significant differences between the CSPH and non‐CSPH groups in the median serum GP73 level (126.8 vs. 73.1 ng/mL, p < 0.001). GP73 level showed a significant positive linear correlation with HVPG (r = 0.459, p < 0.001). The AUC for the diagnosis of CSPH using serum GP73 alone was 0.75 (95% confidence interval [CI] 0.68–0.81). Multivariate logistic regression analysis determined that the levels of GP73, platelets and international normalized ratio were independently associated with CSPH. The combination of these three markers was termed “IP73” score with an AUC value of 0.85 (95% CI 0.80–0.89) for CSPH. Using 0 as a cut‐off value, the specificity and sensitivity of IP73 score were 77.9% and 81.9%, respectively. The IP73 score offers a novel, simple and noninvasive method of assessing CSPH in patients with compensated cirrhosis. A cut‐off value of the IP73 score at 0 can distinguish patients with or without CSPH.

show abstract

“…There is an unmet need for simple, reliable, noninvasive methods to assess CSPH. 7 This is the first study to investigate the association between serum GP73 level and HVPG.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Liu,

Ma,

Chen

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Since these serum biomarkers offer reasonable negative predictive value, they are able to rule out liver fibrosis of advanced stages (e.g., cirrhosis), but their usage is diminished by the potential for false positive results. These serum tests assess fibrosis by including biomarkers that measure the degree of hepatic injury and/or complications of portal hypertension; and/or biomarkers that measure extracellular matrix degradation/fibrogenesis (Agbim & Asrani, 2019; Loomba & Adams, 2020; Rana et al, 2020). Some examples of these serum tests include the NAFLD fibrosis score, BARD score, FIB‐4, aspartate aminotransferase to platelet ratio index and enhanced liver fibrosis score.…”

Section: Hcv Infectionmentioning

confidence: 99%

“…and/or biomarkers that measure extracellular matrix degradation/ fibrogenesis (Agbim & Asrani, 2019;Loomba & Adams, 2020;Rana et al, 2020). Some examples of these serum tests include the NAFLD fibrosis score, BARD score, FIB-4, aspartate aminotransferase to platelet ratio index and enhanced liver fibrosis score.…”

Section: Disease/host Biomarkersmentioning

confidence: 99%

Biomarkers for the clinical development of antiviral therapies

Dorr

Krishnan

et al. 2020

Cytometry Part B Clinical

View full text Add to dashboard Cite

With the morbidity and mortality associated with the COVID‐19 pandemic that we are witnessing this year, the risks posed by emerging viral diseases to global health are all too obvious. This pandemic highlights the importance of antiviral drug discovery, which targets emerging viral pathogens, as well as existing pathogenic viruses that undergo continuous evolution. Drug discovery and development is a long and resource intensive process; however, the use of biomarkers can accelerate clinical development of antivirals by providing information regarding diagnosis of specific viral infections, status of infection, potential safety parameters, and antiviral responses. In clinical practice, many of the biomarkers initially utilized to support clinical development are also used for patient care. While viral load is a standard and essential biomarker used to detect the desired viral suppression induced by an antiviral agent, it has become apparent that additional biomarkers, whether related to the virus, the host or as a consequence of the drug's mechanistic effects, are also important for monitoring clinical outcomes associated with an antiviral therapy. This review summarizes the biomarkers used in the clinical development (as well as in clinical practice, where appropriate) of antiviral therapies for hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and severe acute respiratory syndrome coronavirus 2.

show abstract

Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Diagnostic accuracy of non-invasive methods detecting clinically significant portal hypertension in liver cirrhosis: a systematic review and meta-analysis

Cited by 4 publications

References 68 publications

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

Biomarkers for the clinical development of antiviral therapies

Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About